SYSTEMIC PROSTAGLANDIN E1 ON UREA SYNTHESIS/WHOLE BODY NITRGN METAB IN CIRRHOSIS

全身前列腺素 E1 对尿素合成/肝硬化全身氮代谢的影响

• 批准号: 6115340
• 负责人: ELISABETTA BUGIANESI
• 金额: $ 1.92万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115340
• 关键词: aminoacid metabolism; aminoacid transport; clinical research; drug metabolism; drug screening /evaluation; human subject; human therapy evaluation; liver cirrhosis; liver disorder chemotherapy; nitrogen metabolism; pharmacokinetics; prostaglandin E; urea

The aim of this study is to evaluate the metabolic effects of prostaglandin E1 administration in patients with liver cirrhosis and paired healthy controls. The hypotheses being tested are: 1) Prostglandin E1 significantly influences hepatic and whole body amino nitrogen economy in patients with liver cirrhosis; 2) Prostaglandin E1 produces a decrease in urea synthesis, and 3) Prostaglandin E1 might act on the peripheral tissues, through a decreased amino acid efflux, or increased amino-acid uptake and non-oxidative metabolism. To date 4 subjects have been enrolled. No data analysis has been done.

本研究的目的是评估前列腺素E1给药对肝硬化患者和配对健康对照的代谢影响。 正在检验的假设是：1）前列腺素E1显著影响肝硬化患者的肝脏和全身氨基氮经济; 2）前列腺素E1导致尿素合成减少; 3）前列腺素E1可能通过减少氨基酸流出或增加氨基酸摄取和非氧化代谢作用于外周组织。 迄今为止，已入组4例受试者。 未进行数据分析。